
Your patient saw CAR-T on their social media feed and wants to know if it could help them. Where do you start?
Host Sheila Behimehr, NP talks with Leila Khalili, NP, a rheumatology nurse practitioner and Director of Clinical Research Operations at Hospital for Special Surgery. They cover what CAR-T cells are, why they're called "living drugs," and how a cancer therapy found its way into rheumatology.
You'll also get the full patient journey, from screening to infusion, plus the risks nurses need to know: infection, cytokine release syndrome, and neurotoxicity.
The big takeaway: CAR-T is a journey, not a single appointment. Talk about it early.
Part one of three. Next up: what the data says so far.
More episodes from "Rheumor Has It"



Don't miss an episode of “Rheumor Has It” and subscribe to it in the GetPodcast app.


